指南与共识头颈部肿瘤放疗

基于国际指南高危因素分层的鼻咽癌患者行Ib区豁免调强放疗的可行性

The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
指南 / 共识 · Radiother Oncol · 2023-11-24

研究评估961例非转移性鼻咽癌患者按国际指南推荐预防性Ib区照射的高危因素分为A、B、C三组,C组经倾向评分匹配。A组Ib区复发率最高(11.1%),B组无复发,匹配C组中Ib豁免组与Ib覆盖组复发率均为0.6%(P>0.999)。5年区域无复发生存率在A组、B组及匹配C组中两组间均无显著差异。

要点

  • A组Ib区复发率最高,为11.1%,B组无Ib区复发。
  • 匹配C组中Ib豁免组与Ib覆盖组Ib区复发率均为0.6%(P>0.999)。
  • 5年区域无复发生存率在A组、B组及匹配C组中两组间均无显著差异。

核心结论

  • 对于伴有影像学结外侵犯和/或最大轴径≥2 cm的II区淋巴结的鼻咽癌患者,行Ib区豁免调强放疗可安全实施。
  • 对于存在第一梯队引流结构受累或颌下腺受累的患者,预防性Ib区照射的必要性尚需进一步研究确定。

研究设计与样本

  • 基于国际指南预防性Ib区照射推荐,评估961例非转移性鼻咽癌病例。
  • 采用四项高危因素将患者分为A、B、C三组,并对C组采用倾向评分匹配平衡基线特征,形成匹配C组。

主要发现

  • 在Ib区淋巴结阴性患者中,分别有18例、54例、420例和444例存在第一梯队引流结构受累、颌下腺受累、II区淋巴结影像学结外侵犯和II区淋巴结最大轴径≥2 cm。
  • Ib区复发率在A组最高(11.1%),B组无Ib区复发。
  • 匹配C组中,Ib豁免组Ib区复发率为0.6%,Ib覆盖组为0.6%,P>0.999。
  • 5年区域无复发生存率在A组两组间无显著差异(p=0.208),B组无显著差异(p=0.905),匹配C组无显著差异(p=0.423)。

关键数值与推荐

  • 原文未报告具体推荐条款或关键阈值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To examine the feasibility of level Ib-sparing intensity-modulated radiation therapy (IMRT) in patients with nasopharyngeal carcinoma (NPC) who had high-risk factors classified based on the International Guideline (IG). MATERIALS AND METHODS: We evaluated 961 non-metastatic NPC cases based on IG recommendations for prophylactic Ib irradiation. Four high-risk factors were used to categorise patients into three cohorts: A, B, and C. Propensity score matching was used to balance baseline characteristics in Cohort C, resulting in a matched Cohort C. Recurrence rates at level Ib and regional relapse-free survival (RRFS) rates were evaluated. RESULTS: Among patients with negative Ib lymph nodes (LNs), 18, 54, 420, and 444 exhibited involvement of structures that drain to level Ib as the first echelon (FES), involvement of the submandibular gland (SMG), level II LNs with radiologic extranodal extension (rENE), and level II nodes with a maximal axial diameter (MAD) ≥ 2 cm, respectively. The recurrence rate was highest in Cohort A (11.1 %). Cohort B had no level Ib recurrence. In matched Cohort C, recurrence rates were low in both groups (Ib-sparing group: 0.6 % vs. Ib-covering group: 0.6 %, P > 0.999). No significant differences were observed in 5-year RRFS rates between the two groups in cohort A (p = 0.208), cohort B (p = 0.905), and matched cohort C (p = 0.423). CONCLUSIONS: Level Ib-sparing IMRT could be performed safely for NPC patients with level II LNs who had rENE and/or MAD ≥ 2 cm. Further research should determine the necessity of level Ib prophylactic irradiation for patients with FES or SMG involvement.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Meng Z, Li P, Yang D, et al. The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline. Radiother Oncol. 2023. PMID: 38008418. doi:10.1016/j.radonc.2023.110027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。